Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.56 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | NPY4R | P50391 | 1/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.56 |
| ▸ | NTSR2 | O95665 | 6/20 | 0.56 |
| ▸ | NTSR1 | P30989 | 6/20 | 0.56 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510563 | 0.97 | NTSR2 (0.58) | NTSR2NTSR1SORT1 | |
| SCHEMBL29510574 | 0.90 | F2 (0.62) | OPRD1OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL29793680 | 0.87 | F2 (0.64) | OPRD1OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL30198139 | 0.86 | NPY1R (0.55) | OPRD1OPRM1OPRK1NPY1RNPY2R | |
| SCHEMBL30504141 | 0.85 | NTSR1 (0.57) | OPRD1NTSR2NTSR1SORT1 | |
| SCHEMBL30176449 | 0.85 | CALCR (0.60) | OPRD1OPRM1OPRK1NPY1RNPY2R | |
| SCHEMBL30969929 | 0.84 | F2 (0.58) | NTSR2NTSR1SORT1 | |
| SCHEMBL30637760 | 0.82 | NTSR1 (0.64) | NTSR2NTSR1SORT1 | |
| SCHEMBL29860392 | 0.82 | NTSR1 (0.64) | NTSR2NTSR1SORT1 | |
| SCHEMBL29590984 | 0.82 | NTSR2 (0.49) | NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099533-A1 | ADIPONECTIN PEPTIDOMIMETICS FORMULATIONS | ALLYSTA PHARMACEUTICALS INC (US) | 2025-03-27 | — | — | US | claimed |
| US-12201668-B2 | Adiponectin peptidomimetics formulations | ALLYSTA PHARMACEUTICALS, INC. (US) | 2025-01-21 | — | — | US | claimed |
| US-20230074446-A1 | ADIPONECTIN PEPTIDOMIMETICS FOR TREATING OCULAR DISORDERS | ALLYSTA PHARMACEUTICALS INC (US) | 2023-03-09 | — | — | US | claimed |
| US-20220331393-A1 | ADIPONECTIN PEPTIDOMIMETICS FOR TREATING OCULAR DISORDERS | ALLYSTA PHARMACEUTICALS INC (US) | 2022-10-20 | — | — | US | claimed |
| US-11464825-B2 | Adiponectin peptidomimetics for treating ocular disorders | ALLYSTA PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | claimed |
| EP-4014985-A1 | ADIPONECTIN PEPTIDOMIMETICS FOR TREATING OCULAR DISORDERS | Allysta Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| US-11273197-B2 | Adiponectin peptidomimetics for treating ocular disorders | ALLYSTA PHARMACEUTICALS, INC. (US) | 2022-03-15 | — | — | US | claimed |
| US-20250099533-A1 | ADIPONECTIN PEPTIDOMIMETICS FORMULATIONS | ALLYSTA PHARMACEUTICALS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250099533-A1 | ADIPONECTIN PEPTIDOMIMETICS FORMULATIONS | ALLYSTA PHARMACEUTICALS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-12201668-B2 | Adiponectin peptidomimetics formulations | ALLYSTA PHARMACEUTICALS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12201668-B2 | Adiponectin peptidomimetics formulations | ALLYSTA PHARMACEUTICALS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| JP-2024178262-A | ADIPONECTIN PEPTIDOMIMETICS FORMULATIONS | アリスタ ファーマスーティカルス インク． | 2024-12-24 | — | — | JP | disclosed |
| US-20240382564-A1 | Methods and Compositions for Treating Muscular Dystrophy and Memory Impairment | ALLYSTA PHARMACEUTICALS, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20230021946-A1 | MONOMERIC FUSION PEPTIDES AND METHOD OF USE THEREOF | ALLYSTA PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20220331393-A1 | ADIPONECTIN PEPTIDOMIMETICS FOR TREATING OCULAR DISORDERS | ALLYSTA PHARMACEUTICALS INC (US) | 2022-10-20 | — | — | US | disclosed |
| US-11464825-B2 | Adiponectin peptidomimetics for treating ocular disorders | ALLYSTA PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-107530396-B | Adiponectin peptidomimetics for the treatment of ophthalmic diseases | 雅利斯塔制药公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-4014985-A1 | ADIPONECTIN PEPTIDOMIMETICS FOR TREATING OCULAR DISORDERS | Allysta Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11273197-B2 | Adiponectin peptidomimetics for treating ocular disorders | ALLYSTA PHARMACEUTICALS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| JP-2022505832-A | — | アリスタ ファーマスーティカルス インク． | 2022-01-14 | — | — | JP | disclosed |